top of page
Biosciences
Offspring
Insights & Updates
Surviving the Phase II Cliff: Why So Many Promising Drugs Fail — and What We Can Do About It
For translational leaders, generating decision-quality data before risking millions in clinical trials is crucial. De-Risk Antibody Development with Tissue Insights Platform.
Featured
Search
Operationalizing Translational Success: Why the 5R Framework Demands a Tissue-First Approach
For over a decade, the pharmaceutical industry has universally admired the structured translational frameworks pioneered by industry leaders. When AstraZeneca instituted the "5R Framework" (Right Target, Right Tissue, Right Safety, Right Patient, Right Commercial) and Pfizer deployed their "Three Pillars of Survival" (now the SOCA paradigm), the results were undeniable. AstraZeneca drove their Phase III success rate from a dismal 4% to 19% (1), while Pfizer saw a tenfold impr
evadanielson55
2 days ago4 min read
bottom of page